Jaguar Health: Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2

 Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients

Jaguar Health Inc. (NASDAQ:JAGX) and its wholly owned subsidiary Napo Pharmaceuticals today announced the publication in the peer reviewed journal Breast Cancer Research and Treatment of the results of the investigator-initiated HALT-D trial evaluating crofelemer for preventing chemotherapy-induced diarrhea (CID) in HER2-positive breast cancer patients being treated with trastuzumab, pertuzumab and a taxane. These therapies cause CID in up to 80% of breast cancer patients, reaching grade 3, which often requires hospitalization, in 8-12% of patients. No antidiarrheal medications are currently approved that specifically target the underlying mechanism of CID.

https://www.biospace.com/article/releases/jaguar-health-announces-publication-in-breast-cancer-research-and-treatment-of-investigator-initiated-phase-2-halt-d-study-of-crofelemer-for-prevention-of-chemotherapy-induced-diarrhea-cid-in-breast-cancer-patients/